Amgen Inc. (AMGN) Shares Sold by O Brien Wealth Partners LLC
O Brien Wealth Partners LLC lowered its position in shares of Amgen Inc. (NASDAQ:AMGN) by 5.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,898 shares of the medical research company’s stock after selling 152 shares during the period. Amgen accounts for 0.3% of O Brien Wealth Partners LLC’s portfolio, making the stock its 23rd largest position. O Brien Wealth Partners LLC’s holdings in Amgen were worth $475,000 at the end of the most recent quarter.
A number of other large investors also recently made changes to their positions in AMGN. TrimTabs Asset Management LLC raised its stake in shares of Amgen by 88.9% in the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after buying an additional 288 shares during the period. Alpha Omega Wealth Management LLC raised its stake in shares of Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after buying an additional 100 shares during the period. Jackson Grant Investment Advisers Inc. raised its stake in shares of Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after buying an additional 4 shares during the period. American Beacon Advisors Inc. bought a new stake in shares of Amgen during the first quarter worth about $106,000. Finally, Nelson Roberts Investment Advisors LLC bought a new stake in shares of Amgen during the first quarter worth about $121,000. 79.12% of the stock is owned by institutional investors and hedge funds.
Amgen Inc. (NASDAQ AMGN) traded up 1.238% during mid-day trading on Wednesday, reaching $172.145. The company’s stock had a trading volume of 479,975 shares. Amgen Inc. has a 12-month low of $133.64 and a 12-month high of $184.21. The firm’s 50 day moving average price is $174.35 and its 200 day moving average price is $167.93. The stock has a market cap of $125.61 billion, a price-to-earnings ratio of 15.679 and a beta of 1.35.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. During the same quarter in the prior year, the company posted $2.84 EPS. The company’s quarterly revenue was up 2.1% on a year-over-year basis. On average, equities analysts predict that Amgen Inc. will post $12.57 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Thursday, August 17th will be paid a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a yield of 2.71%. The ex-dividend date is Tuesday, August 15th. Amgen’s payout ratio is 41.93%.
COPYRIGHT VIOLATION NOTICE: This report was first posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.watchlistnews.com/amgen-inc-amgn-shares-sold-by-o-brien-wealth-partners-llc/1495832.html.
A number of research analysts have recently commented on the company. BMO Capital Markets downgraded Amgen from an “outperform” rating to a “market perform” rating and set a $199.00 target price for the company. in a research report on Friday, July 21st. They noted that the move was a valuation call. Jefferies Group LLC reiterated a “hold” rating and set a $180.00 target price on shares of Amgen in a research report on Monday, May 22nd. Leerink Swann reiterated a “market perform” rating and set a $161.00 target price on shares of Amgen in a research report on Thursday, June 22nd. Credit Suisse Group set a $177.00 target price on Amgen and gave the company a “hold” rating in a research report on Friday, July 14th. Finally, Cowen and Company reiterated an “outperform” rating and set a $209.00 target price on shares of Amgen in a research report on Wednesday, April 19th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $186.64.
In related news, SVP Cynthia M. Patton sold 2,922 shares of the stock in a transaction dated Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the transaction, the senior vice president now owns 24,214 shares of the company’s stock, valued at approximately $3,738,641.60. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.20% of the stock is currently owned by corporate insiders.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.